No stock-moving data provided; focus remains on JADE101 Phase 2 data in IgA nephropathy and any future pipeline updates. Interim JADE201 results are years away, so near-term price action likely driven by broader market sentiment and other pipeline catalysts.
Price Chart
Executive Summary
Jade Biosciences announced the first participant has been dosed in a Phase 1 clinical trial of JADE201, a half-life extended, afucosylated anti-BAFF-R monoclonal antibody for autoimmune diseases. Interim data is expected in 2027, so no near-term catalyst is present.
Key Facts
- First participant dosed in FIH Phase 1 trial of JADE201
- JADE201 targets BAFF-R with enhanced effector function and extended half-life
- Interim Phase 1 data expected in 2027
- Preclinical data showed dose-dependent BAFF-R occupancy and sustained B cell depletion
Financial Impact
No financial data disclosed; event is operational milestone with no direct revenue impact.
Risk Factors
- Phase 1 trial may fail to demonstrate safety or efficacy
- Competitors with similar B cell depletion therapies
- Cash burn with no near-term revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301441 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.50 (+3.20%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.50 (+3.20%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 1, 2026 21w ago | 8-K | $18.59 $16.94 | ▼ −8.88% | ▼ −6.13% | $14.50 (−22.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers